Journal: Pharmacological research

Article Title: A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro".

doi: 10.1016/j.phrs.2015.11.017

Figure Lengend Snippet: Figure 4: Cell cycle analysis and p27 and p21 levels in PC3 and DU145 cells exposed to A175.

Article Snippet: Human androgen independent prostate cancer PC3 and DU145 cell lines and the androgendependent LNCaP cell line were originally obtained from American Type Culture Collection (ATCC, Rockville, MD, USA); CWR22Rv1 (Rv1) cells were originally obtained from LeibnitzInstitut DSMZ (Braunschweig, Germany).

Techniques: Cell Cycle Assay

Journal: Pharmacological research

Article Title: A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro".

doi: 10.1016/j.phrs.2015.11.017

Figure Lengend Snippet: Figure 5: Effect of A175 on PC3 and DU145 cell motility.

Article Snippet: Human androgen independent prostate cancer PC3 and DU145 cell lines and the androgendependent LNCaP cell line were originally obtained from American Type Culture Collection (ATCC, Rockville, MD, USA); CWR22Rv1 (Rv1) cells were originally obtained from LeibnitzInstitut DSMZ (Braunschweig, Germany).

Techniques:

Journal: Oncotarget

Article Title: Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

doi:

Figure Lengend Snippet: The graphs indicate growth inhibition curves of OTSSP167 for various types of human cancel cell line; (A) A549 (lung cancer), (B) T47D (breast cancer), (C) DU4475 (breast cancer), and (D) 22Rv1 (prostate cancer) cells, in which MELK is highly expressed, as well as (E) HT1197 (bladder cancer) cell line, in which MELK expression is hardly detectable.

Article Snippet: DU145 cells were injected subcutaneously in the left flank of male BALB/cSLC-nu/nu mice (Japan SLC, Inc.).

Techniques: Inhibition, Expressing

Journal: Oncotarget

Article Title: Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

doi:

Figure Lengend Snippet: Nude mice bearing (A,B) MDA-MB-231 (triple-negative breast cancer), (C,D) A549 (lung cancer), (E) DU145 (prostate cancer), or (F) MIAPaCa-2 (pancreatic cancer) were treated with either vehicle control or OTSSP167 of given concentrations for 14 days. The administration doses were (A) 20 mg/kg intravenously once every two days or (B) 10 mg/kg orally once a day for MDA-MB-231; (C) 1, 5, or 10 mg/kg intravenously once a day or (D) 5 or 10 mg/kg orally once a day for A549; (E) 10 mg/kg orally once a day for DU145; and (F) 10 mg/kg orally once a day for MIAPaCa-2. Mean tumor volumes ± SD (n = 6 for each treatment group) are shown. (G) Lysates of tumor samples taken from A549 and PC-14 xenograft mice were immunoblotted with anti-MELK and anti-ACTB antibodies. (H) OTSSP167 was administered to nude mice bearing PC-14 (MELK-negative bladder cancer cells) at a dose of 10 mg/kg orally once a day. Mean tumor volumes ± SD (n = 3 per group) are shown. i.v. q.2d; intravenously once every two days, i.v. q.d.; intravenously once a day, p.o. q.d.; orally once a day.

Article Snippet: DU145 cells were injected subcutaneously in the left flank of male BALB/cSLC-nu/nu mice (Japan SLC, Inc.).

Techniques: